Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia

Ruxolitinib (rux) Phase II clinical trials are underway for the treatment of high-risk JAK2-rearranged (JAK2r) B-cell acute lymphoblastic leukemia (B-ALL). Treatment resistance to targeted inhibitors in other settings is common; elucidating potential mechanisms of rux resistance in JAK2r B-ALL will...

Descripción completa

Detalles Bibliográficos
Autores principales: Downes, Charlotte E. J., McClure, Barbara J., Bruning, John B., Page, Elyse, Breen, James, Rehn, Jacqueline, Yeung, David T., White, Deborah L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355279/
https://www.ncbi.nlm.nih.gov/pubmed/34376782
http://dx.doi.org/10.1038/s41698-021-00215-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355279/
https://www.ncbi.nlm.nih.gov/pubmed/34376782
http://dx.doi.org/10.1038/s41698-021-00215-x

Ejemplares similares